WASHINGTON/NEW YORK (Reuters) – RFK Jr FDA overhaul pledge came before his selection as President-elect Donald Trump’s health secretary nominee. However, any reforms will encounter resistance from the pharmaceutical industry, which funds much of the agency. The powerful industry’s influence could challenge RFK Jr FDA reform efforts. #RFKJrFDA
Kennedy, known as an environmental activist who has raised doubts about vaccine safety, would oversee crucial public health responsibilities. His authority, if confirmed as Secretary of Health and Human Services, would extend to agencies impacting national health.
Additionally, he would manage government-funded health insurance programs serving over 140 million Americans, including the poor, elderly, and disabled. His role would also cover medical research and other vital areas.
Kennedy has been most vocal about the FDA, an agency that oversees nearly $3 trillion in medicines, food and tobacco products. In interviews and on social media, Kennedy has accused agency staff of doing the bidding of Big Pharma and Big Food. “FDA’s war on public health is about to end,” Kennedy wrote on X in late October. “If you work for the FDA and are part of this corrupt system, I have two messages for you: 1. Preserve your records, and 2. Pack your bags.” FDA officials were not immediately available to comment on the Kennedy nomination.
Shares of vaccine makers, including Pfizer Inc. and Moderna, dropped after news of Kennedy’s appointment, falling up to 2% in after-hours trading. #RFKJrFDA
The Pharmaceutical Research and Manufacturers of America, a major industry lobby group, referred to the drug industry as “a crown jewel.” They expressed their desire to collaborate with the Trump administration to enhance patient health.
The group highlighted significant accomplishments like eradicating polio and smallpox through vaccination. However, it did not directly reference Kennedy in the statement issued after the announcement.
Kennedy ran as an independent candidate in this year’s election. He dropped out in August and endorsed Trump shortly after. In return, he secured a role in the Republican administration.
Pharmaceutical Lobby Faces Off Against RFK Jr FDA Reform Plan
The RFK Jr FDA reform plan is expected to face fierce opposition from powerful pharmaceutical lobbies. Despite this, his approach could push for greater accountability. Ultimately, this conflict may drive necessary changes that could benefit public health, creating a more balanced system.
